ID: ALA190281

Max Phase: Preclinical

Molecular Formula: C22H25BrN6O

Molecular Weight: 469.39

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=c1c(Br)cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n1C1CCCC1

Standard InChI:  InChI=1S/C22H25BrN6O/c23-19-13-15-14-25-22(27-20(15)29(21(19)30)18-3-1-2-4-18)26-16-5-7-17(8-6-16)28-11-9-24-10-12-28/h5-8,13-14,18,24H,1-4,9-12H2,(H,25,26,27)

Standard InChI Key:  PEOPNFFYHMAVJA-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 469.39

Molecular Weight (Monoisotopic): 468.1273

AlogP: 3.82

#Rotatable Bonds: 4

Polar Surface Area: 75.08

Molecular Species: BASE

HBA: 7

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.91

CX LogP: 4.00

CX LogD: 2.48

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.61

Np Likeness Score: -1.20

References

1. Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, Keller PR, McNamara DJ, Sherry D, Zhu T, Brodfuehrer J, Choi C, Barvian MR, Fry DW..  (2005)  Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.,  48  (7): [PMID:15801831] [10.1021/jm049354h]

2. Sánchez-Martínez C, Gelbert LM, Lallena MJ, de Dios A..  (2015)  Cyclin dependent kinase (CDK) inhibitors as anticancer drugs.,  25  (17): [PMID:26115571] [10.1016/j.bmcl.2015.05.100]

Source

Source(1):

• Scientific Literature